Interleukin 15

Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Interleukin 15, Engineering, Doctor of Philosophy, Transposable element, Tumor microenvironment, Immunosuppression, Annual general meeting, IL15, Immortalised cell line, Immunotherapy, Synthetic biology, Efficiency, CAR, RCC, CRISPR, Survival, SITC, Cas9, AML, CD70, Cell, MBA, Biotechnology, Society for Immunotherapy of Cancer, Treatment, Bio, Sofinnova, Hematological Cancer Research Investment and Education Act, Society, Sleeping Beauty transposon system, Catamaran, Vaccine, Medical imaging, Cancer, NK

Catamaran Bio , Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers.

Key Points: 
  • Catamaran Bio , Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers.
  • Collectively, these preclinical data sets demonstrate the power of Catamarans fully-integrated TAILWIND platform to deliver allogeneic NK cell therapies for solid tumors, said Vipin Suri, PhD, MBA, Chief Scientific Officer of Catamaran Bio.
  • We have now shown preclinical efficacy in multiple xenograft models with two differentiated CAR-NK cell therapies engineered with the functional attributes necessary for durable efficacy in solid tumors and manufactured using an efficient non-viral cell engineering system.
  • Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors.

Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT‑179, a HER2-targeted Allogeneic CAR-NK Cell Therapy

Retrieved on: 
Friday, April 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Bio, Express, Immunosuppression, HER2, IL15, Survival, CAR, AACR, DNR, Doctor of Philosophy, Biotechnology, Cell engineering, Interleukin, American Association, Cancer, Interleukin 15, TGF, Ovarian cancer, Association, American Association for Cancer Research, Morph (animation), MBA, Immortalised cell line, Neoplasm, Animal, NK, Data, Pharmaceutical industry, Medical imaging, Vaccine

Catamaran Bio , Inc., a biotechnology company developing allogeneic, offthe-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced preclinical data showing that CAT-179, a cryopreserved, allogeneic HER2-targeted CAR-NK cell therapy, reduces tumor burden and extends survival in a HER2 mouse xenograft model.

Key Points: 
  • Catamaran Bio , Inc., a biotechnology company developing allogeneic, offthe-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced preclinical data showing that CAT-179, a cryopreserved, allogeneic HER2-targeted CAR-NK cell therapy, reduces tumor burden and extends survival in a HER2 mouse xenograft model.
  • CAT-179 demonstrated HER2-CAR-driven interferon gamma production and tumor cell killing in vitro when co-cultured with HER2+ tumor cells.
  • Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors.
  • Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application.

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

Retrieved on: 
Friday, November 12, 2021
SITC, Cancer, Private Securities Litigation Reform Act, Ink, Editas Medicine, Cytokine, Clinical trial, Security (finance), Poster, Technology, Society, NK, Immunotherapy, Research, GAPDH, Annual report, CD16, Selection, Â, Society for Immunotherapy of Cancer, Doctor of Philosophy, Company, Annual general meeting, U.S. Securities and Exchange Commission, GLOBE, Antibody, Therapy, Interleukin 15, Toxicity, Graft-versus-host disease, ADCC, IPSC, Time, Nasdaq, Cell, CRISPR, Vaccine, Pharmaceutical industry

The Company reported these findings in a poster presentation today at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually.

Key Points: 
  • The Company reported these findings in a poster presentation today at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually.
  • iPSC clones were then differentiated into iNKs that were confirmed to express high levels of CD16 and IL-15.
  • IL-15 is important for NK cell survival, and increasing IL-15 expression prolongs the persistence of NK cells.
  • The edited iNK cells were also able to persist for a dramatically longer period of time relative to unedited iNK cells.

Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 8, 2021
Rubius, Spleen, SITC, AML, Cancer immunology, PD-L1, Cancer, Manuscript, G&A, RCT, Therapy, Autoimmunity, Anal cancer, CRO, Clinical trial, R, Food and Drug Administration, Antigen presentation, Initiate, Disease, U.S. FDA, Food, Blood, Society, Investment, NK, Pembrolizumab, HPV, Report, Research, Tumor microenvironment, Red Cell, Company, Annual general meeting, Environment, GLOBE, Degenerative disease, Interleukin 15, RED, Nasdaq, Patient, FDA, El Rubius, Chemotherapy, IND, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Lithium

CAMBRIDGE Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ (RCT) for the treatment of cancer and autoimmune diseases, today reported third quarter 2021 financial results and provided a business update.

Key Points: 
  • The Company thanks her for her contributions to Rubius and wishes her the best in the next chapter of her career.
  • The Company plans to present comprehensive results by the end of 2021 or during the first quarter of 2022.
  • General and administrative (G&A) expenses were flat at $12.0 million during the third quarter of 2021, as compared to the third quarter of 2020.
  • These increases were offset by a decrease in stock-based compensation expense of $1.1 million, following the vesting of large awards early in the third quarter of 2021.

Calypso Biotech Announces First Patient With Celiac Disease Dosed in anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1b Trial, and Extension of Series A to €28M

Retrieved on: 
Thursday, September 9, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology

Calypso Biotech, a leader in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of dosing of first Celiac Disease patient in the Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.

Key Points: 
  • Calypso Biotech, a leader in the development of Interleukin-15 (IL-15) targeted therapies, announces today completion of dosing of first Celiac Disease patient in the Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.
  • Houbiers MD, PhD joined Calypso Biotech as Chief Medical Officer on June 1st.
  • Fountain HealthCare Partners joins renowned syndicate of Gilde Healthcare, Inkef Capital, Johnson & Johnson Innovation - JJDC, Inc. (JJDC), and the companys founding investor M Ventures.
  • Dr. Ena Prosser from Fountains Dublin (Ireland) office has also joined the Board of Calypso Biotech..

Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 9, 2021
Rubius, Investment, Disease, GLOBE, NK, TME, American Association for Cancer Research, Cancer, HPV, Therapy, Memory, Allotransplantation, Nasdaq, Toxic epidermal necrolysis, Tumor microenvironment, Cancer immunology, Clinical trial, Haematopoietic system, Pembrolizumab, Acute myeloid leukemia, Interleukin 15, Initial, Income, Patient, Absence, RECIST, Biopsy, AACR, RED, El Rubius, Association, PD-L1, Manuscript, Safety, Red Cell, G&A, Immunology, American Association, Research, Anal cancer, AML, Nature Communications, R, CRO, Company, Pharmaceutical industry, Fine chemical, Vaccine, Lithium, Medical imaging

CAMBRIDGE Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported second quarter 2021 financial results and provided a business update.

Key Points: 
  • Net loss for the second quarter of 2021 was $50.2 million or $0.56 per common share, compared to $37.9 million or $0.47 per common share in the second quarter of 2020.
  • In the second quarter of 2021, Rubius invested $36.1 million in research and development (R&D) related to its novel RED PLATFORM and towards expanding and advancing its product pipeline, as compared to $26.1 million in the second quarter of 2020.
  • General and administrative (G&A) expenses were $13.9 million during the second quarter of 2021, as compared to $11.6 million for the second quarter of 2020.
  • In addition, during the second quarter, the Company amended its debt facility, postponing principal payments, by two and a half years, until mid-2024.

DGAP-News: CALYPSO BIOTECH SA: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

Retrieved on: 
Monday, November 16, 2020
Branches of biology, Life sciences, Medical specialties, Pharmaceutical industry, Interleukins, Biopharmaceutical, Biotechnology, Pharmacy, Esophagitis, Eosinophilic esophagitis, Interleukin 15, Eosinophil, Celiac Disease and IL-15, Eosinophilic Esophagitis and IL-15, Calypso Biotech BV

Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.

Key Points: 
  • Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15.
  • "CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan to investigate in multiple auto-immune diseases.
  • Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002.
  • Celiac Disease and Eosinophilic Esophagitis are two diseases with high unmet medical need where IL-15 causes inflammation, and tissue destruction.

Beyond Celiac Partners with Provention Bio on Phase 2 Clinical Trial for Promising Celiac Disease Therapeutic

Retrieved on: 
Tuesday, September 22, 2020
Medical specialties, Gluten sensitivity, Clinical medicine, Health, Gastrointestinal tract disorders, RTT, Celiac, Coeliac disease, Gluten, Interleukin 15, Draft:Beyond Celiac

This novel approach to treating celiac disease is designed to block interleukin-15, a cytokine that plays a central role in celiac disease, creating inflammation and intestinal damage.

Key Points: 
  • This novel approach to treating celiac disease is designed to block interleukin-15, a cytokine that plays a central role in celiac disease, creating inflammation and intestinal damage.
  • PRV-015 has shown promising results in earlier studies, making it a therapeutic candidate to watch for treatment in adult celiac disease patients not responding to a gluten-free diet.
  • Provention Bios clinical trial is expected to enroll approximately 220 adults with non-responsive celiac disease and will use the expertise of Beyond Celiac for trial recruitment.
  • Beyond Celiac draws on extensive knowledge of the celiac disease patient community to reach people who are interested in participating in clinical trials.